phone Jaime Mas-Oliva • 011 521 (55)5506-9179 | Pablo Aguilar Islas • 011 521 (55)1091-4385
Welcome to Hamol Biosolutions

"Clever science with a commitment for life"

Hamol Biosolutions LLC is a privately owned specialty biopharmaceutical company focused on the design, development and manufacture of peptide based biologic therapeutics. During the years, the company has assembled a team of expert advisers in all aspects of toxicology, pharmaceutical development, formulation and regulatory affairs.

Headquartered in San Diego, USA, we were established in late 2009 to develop and commercialize proprietary technology that it licensed on an exclusive basis from several academic institutions, both in the USA and Mexico.

About Us

"Developing smart therapeutic strategies to fight disease"

The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. Several of Hamol Biosolutions product line is manufactured under contract by Bioextracto S.A. de C.V., a biotechnology company located in the state of Queretaro in Mexico and with which Hamol Biosolutions has had a close and fruitful relationship for several years.

Although the line of products developed by Hamol Biosolutions encompasses several therapeutic areas, the company has created a strong commitment to the fields of cardiovascular medicine and infection-related research. Hamol Biosolutions close ties with academic institutions, both in the United States of America and Mexico, enable access to promising projects at an early stage. After licensing these projects, the Company performs feasibility and development studies through pre-clinical and clinical levels. Supported by a distinguished panel of scientific advisers and experts in regulation, the Company advances its pipeline through Phase II proof of concept in humans. At this stage, the Company usually seeks a medium size or large pharmaceutical company to complete clinical development and bring the product to market.

Technology Platform

"Delivery value for patients through innovation"

Hamol Biosolutions proprietary technologies and product development obtained though collaboration with academic institutions, gives us the edge in developing innovative possibilities with therapeutically advantageous properties. The ability to combine our understanding of unmet patient needs in the fields of cardiovascular medicine and infection-related research with our cutting edge technology has resulted in original new therapeutic possibilities.

Our competitive advantages include:

  • World-class research and product development.
  • Innovative science and technology platforms.
  • State of the Art manufacturing facilities.

Research Pipeline

Description R&D Preclinical Phase 1 Phase 2


Description R&D Clinical laboratory Market availability

Hamol Biosolutions designs, optimizes and develops peptide-based therapeutics in the fields of atherosclerosis and infection-related conditions such as septic shock. Hamol Biosolutions currently has two early-stage preclinical development programs: HB-ATV-8 a needle free mucosal therapeutic vaccine to prevent and treat atherosclerosis entering Phase 1 development, and HB-SCT-16 a peptide to treat severe complications caused by lipopolysaccharides during Gram-negative bacterial infections. Hamol Biosolutions through its diagnostics program has developed HB-CETP, a diagnostic kit designed to measure the levels of the Cholesterol-Ester Transfer Protein (CETP) in human plasma. This kit is close to validation and son reaching the market.

HB-ATV-8: Patent application Mexico 2012. MX-a-2012-007682. Folio: MX-E-2012-049878. PCT/MX 2013 / 000078.

HB-SCT-16: Patent application in preparation for submission.

HB-CETP: Patent granted Mexico 2007, No. 246945. Patent granted European Community, 2007, No. 1242446. Patent granted United States of America, 2006, No. 7749721 B2. Patent application Canada 2010, No. 2,525,539.

Selected Publications:

P. Mendoza-Espinosa, D. Montalvan-Sorrosa, V. García-González, A. Moreno, R. Castillo and J. Mas-Oliva.
Microenvironmentally controlled secondary structure motifs of apolipoprotein AI derived peptides.
Molecular and Cellular Biochemistry. DOI: 10.1007/s11010-014-2052-2 (2014).

V. García-González, N. Gutiérrez-Q, P. Mendoza-Espinosa, P. Brocos, A. Piñeiro and J. Mas-Oliva.
Key structural arrangements at the C-terminus domain of CETP suggest a potential mechanism for lipid-transfer activity.
Journal of Structural Biology. 186, 19–27 (2014).

Sandra Luz Aguilar-Espinosa, Paola Mendoza-Espinosa, Blanca Delgado-Coello, Jaime Mas-Oliva.
Lecithin-cholesterol acyltransferase (LCAT) activity in the presence of Apo-AI-derived peptides exposed to disorder-order conformational transitions.
Biochemical and Biophysical Research Communications 441:469-473 (2013).

V. García-González, J. Mas-Oliva.
Amyloid fibril formation of peptides derived from the C-terminus of CETP modulated by lipids.
Biochemical and Biophysical Research Communications. 434, 54-59 (2013).

P. Brocos, P. Mendoza-Espinoza, R. Castillo, J. Mas-Oliva and A. Piñéiro.
Multiscale molecular dynamics simulations of micelles: Coarse grain for self- assembly and atomic resolution for fine details.
Soft Matter. 8, 9005-9014 (2012).

A. Jiménez-Corona, S. Damián-Zamacona, A. Pérez-Torres, A. Moreno and J. Mas-Oliva.
Osteopontin upregulation in atherosclerosis is associated with Cellular oxidative stress triggered by the activation of scavenger receptors.
Archives of Medical Research. 43, 102-111 (2012).

J. Campos-Terán, P. Mendoza-Espinosa, R. Castillo and J. Mas-Oliva.
Conformational and Disorder-to-Order Transitions in Proteins: The role of Apolipoprotein Structure and their Function.
In: Protein Interactions. Chapter 17. 1-28 (2011)
ISBN: 979-953-307-885-3

B. Delgado-Coello, MA. Briones-Orta, M. Macías-Silva and J. Mas-Oliva.
Cholesterol: recapitulation of its active role during liver regeneration.
Liver International 31, 1271-1284 (2011).

V. García-González and J. Mas-Oliva.
Amyloidogenic Properties of a D/N Mutated 12 Amino Acid Fragment of the C-Terminal Domain of the Cholesteryl-Ester Transfer Protein (CETP).
International Journal of Molecular Sciences. 12, 2019-2035 (2011).

P. Mendoza-Espinosa, V. García-González, A. Moreno, R. Castillo, and J. Mas-Oliva.
Disorder-to Order Conformational Transitions in Protein Structure and Its Relationship to Disease.
Molecular and Cellular Biochemistry. 330, 105-120 (2009).

P. Mendoza-Espinosa, A. Moreno, R. Castillo and J. Mas-Oliva.
Lipid Dependant Disorder-To-Order Conformational Transitions in Apolipoprotein CI Derived Peptides.
Biochemical and Biophysical Research Communications. 365, 8-15 (2008).

A.L. Alonso, A. Zentella-Dehesa and J. Mas-Oliva.
Characterization of a naturally ocurring new version of the cholesterol ester transfer protein (CETP) from small intestine.
Molecular and Cellular Biochemistry. 245, 173-182 (2003).

V. Bolaños-García, S. Ramos, J. Xicohtencatl-Cortés, R. Castillo y J. Mas-Oliva.
Monolayers of Apolipoproteins at the Air/Water Interface.
Journal of Physical Chemistry B. 105, 5757-5765 (2001).


"June 2014"


Contact Us

"We appreciate your visit to our site and thank you for your interest in our company"


Our products and our services. We invite you to discover the products and services we make available to your company.

Hamol Biosolutions
10145 Via De La Amistad B13
San Diego, California
United States

icon 2 Jaime Mas-Oliva • 011 521 (55)5506-9179

icon 3

icon 2 Pablo Aguilar Islas • 011 521 (55)1091-4385

icon 3

  • Name:

  • E-mail:

  • Message: